Interleukin 27 is up-regulated in patients with active inflammatory bowel disease

Immunologic Research

Volumn 64, Issue 4, 2016, Pages 901-907

  Furuzawa Carballeda, Janette ^a   Fonseca Camarillo, Gabriela ^a   Yamamoto Furusho, Jesús K ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Expression; IBD; Immunoregulatory; Inflammation; Interleukin

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 27; MESSENGER RNA;

ADULT; AGE DISTRIBUTION; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SEX DIFFERENCE; ULCERATIVE COLITIS; UPREGULATION; COLON; DISEASE EXACERBATION; GENETICS; IMMUNOLOGY; INTESTINE MUCOSA; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; COLITIS, ULCERATIVE; COLON; CROHN DISEASE; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; INTERLEUKIN-27; INTESTINAL MUCOSA; MALE; MIDDLE AGED; RNA, MESSENGER; UP-REGULATION;

EID: 84976628460     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-016-8804-z     Document Type: Article

References (18)

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347(6):417–29.
2. Fonseca-Camarillo G, Yamamoto-Furusho JK. Interleukins involved in inflammatory bowel disease as new therapeutic targets. Curr Immunol Rev. 2013;9(2):86–92.
3. Melmed GY, Targan SR. Future biologic targets for IBD: potentials and pitfalls. Nat Rev Gastroenterol Hepatol. 2010;7(2):110–7.
4. Boulay JL, O’Shea JJ, Paul WE. Molecular phylogeny within type I cytokines and their cognate receptors. Immunity. 2003;19(2):159–63.
5. Villarino AV, Huang E, Hunter CA. Understanding the pro- and anti-inflammatory properties of IL-27. J Immunol. 2004;173(2):715–20.
6. Murakami M, Kamimura D, Hirano T. New IL-6 (gp130) family cytokine members, CLC/NNT1/BSF3 and IL-27. Growth Factors. 2004;22(2):75–7.
7. Hölscher C. The power of combinatorial immunology: IL-12 and IL-12-related dimeric cytokines in infectious diseases. Med Microbiol Immunol. 2004;193(1):1–17.
8. Yoh Matsumoto. Is interleukin-27 a real candidate for immunotherapies of multiple sclerosis? Clin Exp Neuroimmunol. 2013;4(1):7–9.
9. Sasaoka T, Ito M, Yamashita J, Nakajima K, Tanaka I, Narita M, Hara Y, Hada K, Takahashi M, Ohno Y, Matsuo T, Kaneshiro Y, Tanaka H, Kaneko K. Treatment with IL-27 attenuates experimental colitis through the suppression of the development of IL-17-producing T helper cells. Am J Physiol Gastrointest Liver Physiol. 2011;300(4):G568–76.
10. Sutherland LR, Martin F, Greer Robinson M, Greenberger N, Saibil F, Martin T, Sparr J, Prokipchuk E, Borgen L. 5-aminosalicylicacid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology. 1987;92(6):1894–8.
11. Henriksen M, Jahnsen J, Lygren I, Sauar J, Kjellevold O, Schulz T, Vatn MH, Moum B. Ulcerative colitis and clinical course: results of a 5-year population based follow-up study (the IBSEN study). Inflamm Bowel Dis. 2006;12:543–50.
12. Harvey RF, Bradshaw JM. A simple index of Crohn’s-disease activity. Lancet. 1980;1(8167):514.
13. Riley SA, Mani V, Goodman MJ, Herd ME, Dutt S, Turnberg LA. Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology. 1988;94(6):1383–9.
14. Mascanfroni ID, Yeste A, Vieira SM, Burns EJ, Patel B, Sloma I, Wu Y, Mayo L, Ben-Hamo R, Efroni S, Kuchr. IL-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39. Nat Immunol. 2013;14(10):1054–1063.
15. Wynick C, Petes C, Gee K. Interleukin-27 mediates inflammation during chronic disease. J Interferon Cytokine Res. 2014;34(10):741–9.
16. Visperas A, Do JS, Bulek K, Li X, Min B. IL-27, targeting antigen-presenting cells, promotes Th17 differentiation and colitis in mice. Mucosal Immunol. 2014;7(3):625–33.
17. Schmidt C, Giese T, Ludwig B, Mueller-Molaian I, Marth T, Zeuzem S, Meuer SC, Stallmach A. Expression of interleukin-12-related cytokine transcripts in inflammatory bowel disease: elevated interleukin-23p19 and interleukin-27p28 in Crohn’s disease but not in ulcerative colitis. Inflamm Bowel Dis. 2005;11(1):16–23.
18. Yamamoto-Furusho JK, Posadas-Sánchez R, Alvarez-León E, Vargas-Alarcón G. Protective role of Interleukin 27 (IL-27) gene polymorphisms in patients with ulcerative colitis. Immunol Lett. 2016;172:79–83.